Wyeth Cold Brand Reformulations Boost Consumer Healthcare Results
This article was originally published in The Tan Sheet
Executive Summary
Total 2007 first-quarter net revenue for Wyeth Consumer Healthcare increased 10 percent to $611 million, primarily due to increased cough and cold product sales as the segment continues to recover from restrictions placed on pseudoephedrine products in 2006, according to the firm
You may also be interested in...
Wyeth’s Advil PM Approved By FDA; Sleep Aid To Challenge Tylenol PM?
Wyeth is entering the combination sleep aid/pain reliever category with its new Advil PM, recently approved by FDA for over-the-counter sale
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement